MRI-AST(MAST)评分可准确预测主要不良肝脏结局、肝细胞癌、肝移植和肝病相关死亡
本回顾性分析纳入346例非酒精性脂肪性肝病患者,评估MAST评分与主要不良肝脏结局、肝细胞癌、肝移植及肝病相关死亡的关系。中位随访29.5个月,MAST每增加1个logit单位,不良事件风险比为2.01(95%CI 1.59-2.54;P<.0001),C统计量为0.919(95%CI 0.865-0.953)。结论认为MAST评分可无创识别高危非酒精性脂肪性肝炎并准确预测上述结局。
要点
- MAST评分每增加1个logit单位,不良事件风险比2.01(95%CI 1.59-2.54;P<.0001)。
- MAST 0.165-0.242组不良事件风险比7.75(95%CI 1.40-42.9;P=.0189),以0-0.165为参照。
- MAST 0.242-1.0组不良事件风险比22.11(95%CI 6.59-74.2;P<.0000),以0-0.165为参照。
核心结论
- MAST评分可无创识别高危非酒精性脂肪性肝炎,并准确预测主要不良肝脏结局、肝细胞癌、肝移植和肝病相关死亡。
研究设计与样本
- 回顾性分析纳入2013年至2022年一家三级医疗中心的非酒精性脂肪性肝病患者,均在6个月内完成磁共振成像质子密度脂肪分数、磁共振弹性成像和实验室检查。
- 排除其他慢性肝病病因,共346例患者,平均年龄58.8岁,女性占52.9%,2型糖尿病占34.4%。
- 采用Cox比例风险回归模型计算logit MAST与主要不良肝脏结局(腹水、肝性脑病或食管静脉曲张出血)、肝移植、肝细胞癌或肝病相关死亡的的风险比。
- 以MAST评分0.000-0.165为参照组,计算MAST评分0.165-0.242和0.242-1.000与主要不良肝脏结局或死亡的风险比。
主要发现
- 平均丙氨酸氨基转移酶50.7 IU/L(24.3-60.0 IU/L),天冬氨酸氨基转移酶38.05 IU/L(22.00-41.00 IU/L),血小板242.9 × 109/L(193.8-290.0 × 109/L)。
- 质子密度脂肪分数12.90%(5.90%-18.22%),磁共振弹性成像肝硬度2.75 kPa(2.07-2.90 kPa),中位随访29.5个月。
- 14例发生不良结局,包括10例主要不良肝脏结局、1例肝细胞癌、1例肝移植和2例肝病相关死亡。
- MAST每增加1个logit单位,不良事件风险比2.01(95%CI 1.59-2.54;P<.0001),Harrell一致性统计量(C统计量)0.919(95%CI 0.865-0.953)。
- MAST评分0.165-0.242和0.242-1.0相对于0-0.165的不良事件风险比分别为7.75(95%CI 1.40-42.9;P=.0189)和22.11(95%CI 6.59-74.2;P<.0000)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The MRI-AST (MAST) score accurately identifies patients with at-risk nonalcoholic steatohepatitis, defined as nonalcoholic steatohepatitis with nonalcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2 at highest risk for disease progression. It is important to determine the robustness of the MAST score in predicting major adverse liver outcomes (MALO), hepatocellular carcinoma (HCC), liver transplant, and death. METHODS: This retrospective analysis included patients with nonalcoholic fatty liver disease from a tertiary care center who underwent magnetic resonance imaging proton density fat fraction, magnetic resonance elastography, and laboratory testing within 6 months from 2013 to 2022. Other causes of chronic liver disease were excluded. Hazard ratios between logit MAST and MALO (ascites, hepatic encephalopathy, or bleeding esophageal varices), liver transplant, HCC, or liver-related death were computed using a Cox proportional hazards regression model. We computed the hazard ratio of MALO or death associated with MAST scores 0.165-0.242 and 0.242-1.000, using MAST scores 0.000-0.165 as the reference group. RESULTS: Among 346 total patients, average age was 58.8 years with 52.9% females and 34.4% with type 2 diabetes. Average alanine aminotransferase was 50.7 IU/L (24.3-60.0 IU/L), aspartate aminotransferase was 38.05 IU/L (22.00-41.00 IU/L), platelets were 242.9 × 109/L (193.8-290.0 × 109/L), proton density fat fraction was 12.90% (5.90%-18.22%), and liver stiffness on magnetic resonance elastography was 2.75 kPa (2.07-2.90 kPa). Median follow-up was 29.5 months. Fourteen had adverse outcomes, including 10 MALO, 1 HCC, 1 liver transplant, and 2 liver-related deaths. The Cox regression of MAST versus adverse event rate had a hazard ratio of 2.01 (95% confidence interval, 1.59-2.54; P < .0001) for each 1 logit unit increases in MAST. The corresponding Harrell concordance statistic (C statistic) was 0.919 (95% confidence interval, 0.865-0.953). The MAST score ranges of 0.165-0.242 and 0.242-1.0, respectively, had adverse event rate hazard ratio of 7.75 (1.40-42.9; P = .0189) and 22.11 (6.59-74.2; P < .0000) relative to MAST 0-0.165. CONCLUSIONS: The MAST score noninvasively identifies at-risk nonalcoholic steatohepatitis and accurately predicts MALO, HCC, liver transplant, and liver-related death.
引用
- Truong E, Gornbein JA, Yang JD, et al. MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. Clin Gastroenterol Hepatol. 2023. PMID: 36813013. doi:10.1016/j.cgh.2023.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。